IAIN MACDOUGALL, King’s College Hospital, London
REFERENCE: The Lancet, 2006, 368: 947-53
The use of recombinant erythropoietin for treating anaemia may soon be supplemented by a range of targeted molecular agents, including an oral drug. In the Lancet, Iain Macdougall from King’s College Hospital in London has reviewed new strategies under clinical investigation for stimulating the growth of red cells, which, he told Peter Goodwin, will potentially expand access to effective treatments for anaemic patients worldwide.
The use of recombinant erythropoietin for treating anaemia may soon be supplemented by a range of targeted molecular agents, including an oral drug. In the Lancet, Iain Macdougall from King’s College Hospital in London has reviewed new strategies under clinical investigation for stimulating the growth of red cells, which, he told Peter Goodwin, will potentially expand access to effective treatments for anaemic patients worldwide.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.